Johnson & Johnson Q3 2021 Earnings Report

Reported solid performance driven by Pharmaceuticals, Medical Devices recovery, and Consumer Health growth.

Key Takeaways

Johnson & Johnson reported a total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%. Earnings per share increased by 3.0% to $1.37, and adjusted earnings per share increased by 18.2% to $2.60. The company is increasing its 2021 full-year guidance.

Total sales growth of 10.7% to $23.3 Billion.

Operational growth of 9.9% and adjusted operational growth of 10.6%.

Earnings per share of $1.37, a 3.0% increase.

Adjusted earnings per share of $2.60, an 18.2% increase.

Total Revenue

$23.3B

Previous year: $21.1B